Alginate biomaterials for the treatment of hepatic disorders

US9387222B2 · kind B2 · utility

Assignees

• HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. · IL
• BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY · IL

Inventors

• Yaron Ilan · Kfar Tavor, IL
• Gadi Lalazar · Mevaseret Tsiyon, IL
• Eyal Shteyer · Mevaseret Tsiyon, IL
• Ami Ben-Yaakov · Jerusalem, IL
• Smadar Cohen · Beer Sheva, IL
• Tsiona Elkayam · Afula, IL

Key dates

• Filing date: Nov 27, 2008
• Grant date: Jul 12, 2016
• Expiry date: Nov 27, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P1/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.